David A. Glocker, Ph.D., Joins Biophan Technologies Scientific Advisory Board; Authority in Thin Film Coatings Headed Kodak Thin Film Research Group.

ROCHESTER, N.Y. -- Biophan Technologies, Inc. (OTC BB:BIPH), a developer of next-generation biomedical technology, has announced that David A. Glocker, Ph.D., a leader in thin film coating technologies and magnetron equipment, has joined the Biophan Scientific Advisory Board.

Dr. Glocker is President of Isoflux Incorporated, a manufacturer of magnetron equipment, which he founded in 1993 (http://www.isofluxinc.com). He has more than 20 years of experience in thin film research, development, and manufacturing and has taken a number of new processes from laboratory-scale feasibility studies through successful production. Dr. Glocker formerly headed a thin film R&D group for the Eastman Kodak Company.

In addition to serving on the Scientific Advisory Board, Dr. Glocker will work with Dr. Xingwu Wang, of Alfred University and a co-founder of Biophan subsidiary Nanoset LLC, to develop advanced coatings for MRI image compatibility. Dr. Glocker will also assist in the transition of Dr. Wang's coating technologies from laboratory to commercial utilization in customer sites.

Dr. Glocker is an inventor or co-inventor of 25 U.S. patents and an author of more than 25 research papers in the areas of sputter source design, plasmas and plasma characteristics, sources of substrate heating in sputtering, and the control of sputtering processes and sputtered film properties. He also is the co-editor of The Handbook of Thin Film Process Technology, a major reference work in the field.

"We are extremely pleased to welcome Dr. Glocker to the Biophan Scientific Advisory Board," stated Michael Weiner, Biophan CEO. "Our technologies are at the leading edge of advanced materials science and nanotechnology. Dave has proven experience working with large and small companies and in developing and implementing coating processes in large-scale production environments, such as Kodak's film business. Dave's unique processes for coating cylindrical objects will be particularly valuable in helping our customers who need to coat pacemaker, defibrillator, and neurostimulator leads, guidewires, catheters, and stents, as well as other cylindrical objects to adopt our coating processes to their high speed manufacturing lines."

About Biophan Technologies

Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and compatible with the magnetic resonance imaging (MRI) environment. The Company develops enabling technologies for implanted medical systems such as pacemakers, and interventional surgical devices such as catheters and guidewires, as well as stents and other implants that can be safely and effectively imaged under MRI. The technology is also being used to create MRI contrast agents, and has expanded to include other applications, such as drug delivery and power systems derived from body heat. Four Biophan product lines include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors have 21 issued U.S. patents and 71 patents pending, in areas including nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development arrangements with Boston Scientific (NYSE:BSX) and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. For more information, please visit www.biophan.com.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements included in this press release may constitute forward-looking statements. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors including, but not limited to: the development of Biophan's MRI technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the acceptance by the market of Biophan's products; competition and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.